UBS’s Protalix BioTherapeutics PLX Stock Holding History

UBS’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-1,000	Closed	-$37K	–	10651
2014 Q2	$37K	Buy	+1,000	New	+$40.3K	﹤0.01%	7281
2014 Q1	–	Sell	-160	Closed	-$6K	–	10700
2013 Q4	$6K	Sell	160 -410	-72%	-$17.3K	﹤0.01%	9440
2013 Q3	$26K	Buy	570 +220	+63%	+$11.3K	﹤0.01%	7720
2013 Q2	$17K	Buy	+350	New	+$18.6K	﹤0.01%	8081

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

UBS's PLX Position: Q3 2014 in Review

UBS reduced its Protalix BioTherapeutics (PLX) stake by 53% in Q3 2014, selling an estimated $2.59K and leaving 80 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #10008.

UBS first reported a position in PLX in Q2 2013 and has held it in 6 quarters since. The position peaked at $1.09M in Q3 2013. 43 funds tracked by Wall St. Rank hold PLX as of Q3 2014.

UBS held 80 shares of Protalix BioTherapeutics worth $2K as of Q3 2014.
UBS sold 90 Protalix BioTherapeutics shares in Q3 2014, an estimated $2.59K.
Protalix BioTherapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10008 holding.
UBS first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 6 quarters since.
UBS's Protalix BioTherapeutics position peaked at $1.09M in Q3 2013.
43 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.